您現在的位置 :

醫療團隊

專業的醫護人員，提供最佳的醫療服務

醫師介紹

  •

蘇祐立醫師

泌尿上皮癌、大腸直腸癌、腎臟癌、攝護腺癌、軟組織肉瘤、癌症精準藥物治療、免疫治療、新藥臨床試驗
  • 國語,英語,閩南語
  • 副教授
醫師網路掛號
直接點選進入醫師網路掛號畫面
醫師資歷
  • 現職
    • 高雄長庚血液腫瘤科副科主任
    • 高雄長庚血液腫瘤科主治醫師
  • 學歷
    • 中國醫藥大學 中醫系雙主修醫學士
  • 經歷
    • 高雄長庚血液腫瘤科主治醫師
  • 學會與認證
    • 中華民國癌症醫學會
    • 台灣內科醫學會
  • 論文及期刊發表
    • Galectin-1 overexpression activates the FAK/PI3K/AKT/mTOR pathway and is correlated with upper urinary urothelial carcinoma progression and survival. Cells 2020, 9(4):806 (SCI; IF=4.366; Cell biology, 70/195 First and corresponding author)

      Su YL*, Luo HL, Huang CC, Liu TT, Huang EY, Sung MT, Lin JJ, Chiang PH, Chen YT, Kang CH, Cheng YT.
    • Androgen deprivation therapy for prostate cancer and the risk of hematologic disorders. PLos One 2020; 15(2):e0229263. (SCI; IF=2.740; Multidisciplinary sciences 27/71)

      Liu JM, Liu YP, Chuang HC, Wu CT, Su YL, Hsu RJ.
    • Sequential Circulating Tumor Cell Counts in Patients with Locally Advanced or Metastatic Hepatocellular Carcinoma: Monitoring the Treatment Response. J Clin Med 2020; 9(1): E188. (SCI; IF=3.303; Medicine, General & internal 36/165)

      Rau KM, Liu CT, Hsiao YC, Hsiao KY, Wang TM, Hung WS, Su YL, Liu WC, Wang CH, Hsu HL, Chuang PH, Cheng JC, Tseng CP.
    • Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial. Lancet Oncol 2019. (SCI; IF=33.752; Oncology 4/244)

      Petrylak DP, de Wit R, Chi KN…Su YL…et al.
    • A Narrative Review of Complementary Nutritional Supplements for Chemotherapy-induced Peripheral Neuropathy. Altern Ther Health Med 2019 (SCI; IF=0.937; Integrative complementary medicine 25/28)

      Liu YW, Liu CT, Su YL, Tsai MY.
    • Comparative study of the safety and efficacy of first-line cisplatin and carboplatin chemotherapy in elderly patients with metastatic urothelial carcinoma. Oncology 2020;98:146-153 (SCI; IF=2.642; Oncology 162/244, Corresponding author)

      Huang SY, Wu CC, Hsieh MC, Rau KM, Chiang PH, Sung MT, Luo HL, Huang CC, Huang CH, Liu JM, Su YL*.
    • Aristolochic Acid Affects Upper Tract Urothelial Cancer Behavior through the MAPK Pathway. Molecules 2019, 24(20): 3707. (SCI; IF=3.267; Chemistry, multidisciplinary 70/177)

      Luo HL, Chen IH , Su YL, Huang CC, Chiang PH, Yu CC, Lee NL, Lin JJ, Sung MT*.
    • Presence of Chronic Obstructive Pulmonary Disease (COPD) Impair Survival in Lung Cancer Patients Receiving Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor (EGFR-TKI): A Nationwide, Population-Based Cohort Study. J Clin Med 2019, 8(7):1024. (SCI; IF=3.303; Medicine, General & internal 36/165, Corresponding author)

      Wu CC, Rau KM, Lee WC, Hsieh MC, Liu JC, Chen YY, Su YL*.
    • Methylation of SPARCL1 Is Associated with Oncologic Outcome of Advanced Upper Urinary Tract Urothelial Carcinoma. Int J Mol Sci 2019; 20(7):E1653. doi: 10.3390/ijms20071653. (SCI; IF=4.556; Biochemistry & Molecular Biology 74/297)

      Luo HL, Chiang PH, Huang CC, Su YL, Sung MT, Tsai EM, Lin CS, Chiang PH*.
    • Developing a multivariable normal tissue complication probability model to predict late rectal bleeding following intensity-modulated radiation therapy. J Cancer 2019; 10(11):2588-2593. (SCI; IF=3.565; Oncology 105/244)

      Huang CC, Chao PJ, Guo SS, Wang CJ, Luo HL, Su YL, Lee TF, Fang FM*.
    • Gender is a significant prognostic factor for upper urinary tract urothelial carcinoma: A large hospital-based cancer registry study in an endemic area. Front. Oncol. 9:157. (SCI; IF=4.848; Oncology 69/244)

      Huang CC, Su YL, Luo HL, Chen YT, Sio TT, Hsu HC, Lai CH*.
    • Proteomics analysis of Tangeretin-induced apoptosis through mitochondrial dysfunction in bladder cancer cells. Int J Mol Sci 2019; 20:E1017. (SCI; IF=4.556; Biochemistry & Molecular Biology 74/297)

      Lin JJ, Huang CC, Su YL, Luo HL, Lee NL, Wu YJ, Sung MT *.
    • A review of Complementary therapies with medicinal plants for chemotherapy-induced peripheral neuropathy. Complement Ther Med 2019; 42:226-323. (SCI; IF=2.063; Integrative & Complementary medicine 14/28)

      Wu BY, Liu CT, Su YL, Chen SY, Chen YH, Tsai MY*.
    • Impact of Prognostic Nutritional Index on Overall Survival for Patients with Metastatic Urothelial Carcinoma. J Cancer 2018, 14;9(14):2466-2471. (SCI; IF=3.565; Oncology 105/244, Corresponding author)

      Hsieh MC, Rau KM, Chiang PH, Sung MT, Lan J, Luo HL, Huang CC, Huang CH, Su YL*.
    • Hand-foot skin reaction predicts treatment outcome of pazopanib in patients with metastatic soft tissue sarcoma: A multicenter study in the Asian population. Asia Pac J Clin Oncol 2018, 14:353-360. (SCI; IF=2.012; Oncology 201/244)

      Huang PW, Chou WC, Shen WC, Hung CY, Huang KG, Su YL, Lu CH, Chang YS, Liau CT*.
    • Prognostic impact of tumor infiltrating lymphocytes on patients with metastatic urothelial carcinoma receiving platinum based chemotherapy. Sci Rep. 2018; 8(1):7485. (SCI; IF=3.998; Multidisciplinary Sciences 17/71)

      Huang HS, Su YL, Li PH, Chiang PH, Huang CH, Chen CH, Hsieh MC*.
    • Reintroducing Pazopanib Reverses the Primary Resistance of Nivolumab in a Patient with Metastatic Clear-cell Renal Cell Carcinoma. Clin Genitourin Cancer. 2018; 16(2):114-6. (SCI; IF=2.695; Urology & Nephrology 30/85)

      Su YL*.
    • High expression of endoglin in primary breast cancermay predict response to neoadjuvant chemotherapy. Mol Med Rep. 2017; 16(5):7185-7190. (SCI; IF=2.100; Medicine, research & experimental 96/138)

      Rau KM*, Su YL, Li SH, Hsieh, MC Wu CC, Chou FF, Chiu Tai Jan, Chen Yen, Hao, Liu Chien Tin.
    • Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial. Lancet. 2017; 390(10109):2266-2277. (SCI; IF=60.392; Medicine, General & internal 2/165)

      Petrylak DP, de Wit R, Chi KN…Su YL…et al.
    • Therapeutic outcome of nasopharyngeal carcinoma with cranial nerve palsy: a single institution experience of 104 patients. OncoTargets Ther. 2017 Apr10;10:2069-2075. (SCI; IF=3.337; Biotechnology & applied microbiology 56/156)

      Huang CC*, Fang FM, Chen HC, Hsu HC, Huang TL, Su YL, Chang YC.
    • Novel Inflammation-Based Prognostic Score for Predicting Survival in Patients with Metastatic Urothelial Carcinoma. PLOS One 10(6): e0129268. (SCI; IF=2.740; Multidisciplinary sciences 27/71, first author)

      Su YL, Hsieh MC, Chiang PH, Sung MT, Lan J, Luo HL, Huang CC, Hung CH, Tang Y, Rau KM*.
    • Left ventricular intracavitary and intramyocardial metastases from renal cell carcinoma. J Echocardiogr. 2017; 15(3):143-144. (non-SCI)

      Lee WC, Liu WH, Su YL*.
    • A preliminary randomised controlled study of short-term Antrodia cinnamomea treatment combined with chemotherapy for patients with advanced cancer. BMC Complement Altern Med 2016; 16(1):322. (SCI; IF=2.833; Integrative & Complementary medicine 6/28)

      Tsai MY, Hung YC, Chen YH, Chen YH, Huang YC, Kao CW, Su YL, Chiu HH, Rau KM*.
    • Tailored Selection of First-Line Cisplatin-Based Chemotherapy in Patients with Metastatic Urothelial Carcinoma of Bladder. J Cancer 2016; 27:1347-52. (SCI; IF=3.565; Oncology 105/244, Corresponding author )

      Hsieh MC, Huang CH, Chiang PH, Chen YY, Tang Y, Su YL*.
    • The efficacy and safety of everolimus for the treatment of progressive gastroenteropancreatic neuroendocrine tumors: A multi-institution observational study in Taiwan. Asia Pac J Clin Oncol 2016; 12(4):396-402. (SCI; IF=2.012; Oncology 201/244)

      Liu CT, Chen MH, Chen JS, Chen LT, Shan YS, Lu CH, Su YL, Ku FC, Chen YY, Chou WC*.
    • Prognostic model to predict survival in patients with metastatic upper tract urothelial carcinoma treated with cisplatin-based chemotherapy. Int J Urol 2016; 23:385-389. (SCI; IF=2.445; UROLOGY & NEPHROLOGY 36/85)

      Hsieh MC, Su YL, Chiang PH, Rau KM, Chen YY, Huang CH*.
    • The comparison of oncologic outcomes between metastatic upper tract urothelial carcinoma and urothelial carcinoma of the bladder after cisplatin-based chemotherapy. Urol Oncol. 2015 Nov;33(11):495.e9-14. (SCI; IF=2.882; UROLOGY & NEPHROLOGY 28/85)

      Hsieh MC, Chiang PH, Rau KM, Chen YY, Su YL, Huang CH*
    • Asthma and Risk of Prostate Cancer: A Population-based Case-Cohort Study in Taiwan. Medicine, 2015; 94(36): e1371. (SCI ; IF=1.552 MEDICINE, GENERAL & INTERNAL 89/165)

      Su YL, Chou CL, Rau KM, Charles Lee TC*.
    • The Prognostic Impact of Histopathological Variants in Patients with Advanced Urothelial Carcinoma. PLoS One. 2015 Jun 26;10(6):e0129268. (SCI; IF=2.740; Multidisciplinary sciences 27/71; Corresponding author)

      .Hsieh MC, Sung MT, Chiang PH, Huang CH, Tang Y, Su YL*
    • Adding Bevacizumab to Chemotherapy Effectively Control Radioresistant Brain Metastases in ALK-positive Lung Adenocarcinoma. J Thorac Oncol. 2015; 10(4):e21-22 (SCI ; IF=13.357 ; Respiratory System 3/64)

      Su YL, Rau KM*.
    • Post-mastectomy radiotherapy benefits subgroups of breast cancer patients with T1-2 tumor and 1-3 axillary lymph node(s) metastasis. Radiology and oncology. 2014;48:314-322. (SCI ; IF=1.746 ; Radiology, Nuclear medicine & Medical imaging 92/133;first author)

      Su YL, Li SH, Chen YY , Chen HC, Tang Y, Huang CH, Chou FF, Wu SC, Rau KM*.
    • Intra-arterial chemotherapy with doxorubicin and cisplatin is effective for advanced hepatocellular cell carcinoma. Sci World J. 2014:160138 (non-SCI).

      Ma MC, Chen YY, Li SH, Cheng YF, Wang CC, Chiu TJ, Pei SN, Liu CT, Huang TL, Huang CH, Su YL, Chen YH, Lu SN, Rau KM*.